Skip to main content
The Clinic reception at the Charles Perkins Centre

Register your interest for a clinical trial

Evaluating treatments for obesity and eating disorders

We can't do research without your help. If you need help losing weight, preventing or managing Type 2 Diabetes, you may be eligible to participate in a clinical trial at the Boden Collaboration.

To be eligible to participate in a trial at the Boden Collaboration you must meet the following criteria: 

  • Age 18+ years
  • BMI > 25kg/m2
  • And/or Type 2 Diabetes

If accepted to take part, patients will receive:

  • Free medical care in a clinical trial
  • Advice and counselling from a range of health professionals including dietitians
  • Regular medical monitoring including blood tests

You will be medically supervised and there will be no costs involved. You will also be reimbursed for your travel expenses.

For more information, with no obligation:

PH: (02) 8627 0101
E: clinicaltrials.boden@sydney.edu.au
 

Current clinical trials

This is a randomised, active comparator, double blind study to determine the efficacy of the experimental medication Tirzepatide (up to a maximally tolerated dose of 15mg/week) compared to Dulaglutide (1.5mg/week) for preventing major cardiovascular events in 12,500 participants over a timeframe of 5-6 years.

Participants will receive one of the interventions which is self-administered by subcutaneous injection (similar to insulin) once a week. Participants will attend visits at the Charles Perkins Centre, Royal Prince Alfred clinic once a month for the first 6 months and then once every 3 months until the end of the study.

The objective of this study is to prove the non-inferiority and then superiority of Tirzepatide compared to Dulaglutide for preventing cardiovascular events such as myocardial infarction (heart attack) and cerebrovascular accident (stroke) in people who have established cardiovascular disease.  

A secondary objective is to determine the effect of Tirzepatide on weight, HbA1c and blood lipids. A previous study comparing Tirzepatide to Dulaglutide (1.5mg) showed greater weight loss and reduction in HbA1 and serum triglycerides in participants treated with Tirzepatide.

Eligibility

  • Age ≥ 40 years
  • Body Mass Index ≥ 25kg/m2
  • Diagnosis of Type II diabetes
  • Established cardiovascular disease (heart disease, cerebrovascular disease or peripheral vascular disease)
  • Hba1c 7-10.5%

This study is being sponsored by Eli Lilly Australia Pty Ltd and conducted at the Boden Collaboration, The University of Sydney at the Charles Perkins Centre.

This study has been approved by the Ethics Review Committee (RPAH Zone of the Sydney Local Health District (protocol number X20-0097).

For more information or to register your interest please contact the researchers on 8627 0101 or clinicaltrials.boden@sydney.edu.au

This is a 16-week, phase II, randomised, parallel group study to investigate the effects of the injectable study drug BI 456906 compared with placebo and open-label semaglutide in patients with Type II diabetes mellitus.

BI 456906 is a dual acting agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors. In patients with Type II diabetes, overweight and obesity, BI 456906 is expected to result in improved HbA1c and body weight loss.

Participants will be randomly allocated to a dose of BI 456906 or placebo once or twice weekly or semaglutide which is weekly. Participants will attend visits at the Charles Perkins Centre, Royal Prince Alfred clinic once or twice weekly for eight weeks and then monthly for the following two months.

Those in the BI 456906 groups or placebo will be blinded so neither the researchers nor the participants know what dose regime of medication has been allocated to each participant. The semaglutide group will be open label, meaning both the researchers and the participant will be aware of what they are taking.

Key eligibility criteria:

  • 18 to 75 years old
  • Diagnosis of Type II diabetes 
  • HbA1c 7% - 10% 
  • Currently taking Metformin ³ 1000mg/day
  • BMI: 25 kg/m2 – 50kg/m2

This study is being sponsored by Boehringer Ingelheim Pharmaceuticals, Inc and conducted at Boden Collaboration, The University of Sydney at the Charles Perkins Centre.

This study has been approved by the Ethics Review Committee: RPAH Zone of the Sydney Local Health District (protocol number X20-0107).

For more information or to register your interest please contact the researchers on 8627 0101 or clinicaltrials.boden@sydney.edu.au